Uppsala, Sweden, 2014-03-06 08:58 CET (GLOBE NEWSWIRE) --
THIRD QUARTER November 1, 2013 – January 31, 2014
- Consolidated Net sales amounted to € 2 thousand (0) [1]
- Operating income amounted to € - 3,221 thousand (-1,628)
- Net income after tax amounted to € - 3,440 thousand (-1,757)
- Earnings per share amounted to € - 0.04 (-0.02)
- Comprehensive income amounted to € - 3,440 thousand (-1,757)
- FDA approved Oasmia’s production facility in Uppsala
- Increased financing by extension of the MSEK 105 loan from Nexttobe AB and a new MSEK 40 bank loan.
THE PERIOD May 1, 2013 – January 31, 2014
- Consolidated Net sales amounted to € 5 thousand (0)
- Operating income amounted to € -7,105 thousand (-5,162)
- Net income after tax amounted to € -7,610 thousand (-5,587)
- Earnings per share amounted to € -0.09 (-0.09)
- Comprehensive income amounted to € -7,610 thousand (-5,587)
-
Oasmia initiated a clinical program for Paclical for treatment of breast cancer
- Oasmia initiated pre-clinical studies with OAS-19, the first pharmaceutical project with a combination of two active cytostatics in one infusion
EVENTS AFTER CLOSING DAY
- Oasmia is granted conditional FDA approval for Paccal Vet
[1]The numbers in brackets concern results from the corresponding period of the previous year
